In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, shares best practices for reducing greenhouse gas emissions across distribution channels without disrupting supply chain efficiency.

Is the industry ready for the Aug. 1 deadline of when these levies go into effect?

In the second part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of supply chain operations & distribution services, discusses the advanced technology and data-driven solutions that are proving most effective in enhancing real-time visibility and operational efficiency.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle details how manufacturers can overcome the data gaps from suppliers and third parties when aiming for sustainability certifications or ESG reporting compliance.

A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.

In the first part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of supply chain operations & distribution services, outlines how the industry's distribution strategy is evolving to ensure timely, safe, and compliant delivery.

In the final part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, discusses the potential repercussions of telehealth companies selling GLP-1s.

The new deal imposes 15% tariffs on most EU exports, including pharmaceuticals.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, dives into the metrics pharma companies can track today in order to measure distribution-related sustainability performance.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, explains the meaning behind Scope 3 emissions, including why they pose such a challenge for pharma manufacturers.

Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, stakeholder engagement, and innovative access strategies are key to long-term CGT success.

In the fourth part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains the market dynamics or stakeholder misalignments that need to be resolved in order for the next generation of weight-loss drugs to reach scale without overburdening payers.

Agreement allows educational institutions to access cold chain packaging solutions without the typical request for proposal process, supporting research, lab operations, and healthcare training.

In the fifth part of this roundtable discussion, a panel of KOLs explore how the chain of custody and chain of ownership are impacted by supply chain challenges, such as last-mile distribution and DSCSA data security.

As new pricing and trade policies take shape, 60% of life sciences and healthcare executives anticipate business disruption, according to a new survey from Deloitte.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, covers the operational or strategic steps that pharma executives ought to be taking now in order to mitigate risks while awaiting clarity on tariff implementation.

These innovations are revolutionizing pharmaceutical packaging by enhancing drug safety, combating counterfeiting, ensuring regulatory compliance, and improving patient adherence across the supply chain.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the role digital supply chain tools and analytics can play in helping manufacturers respond to pricing and sourcing volatility caused by sudden policy shifts.

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.

In the third part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, outlines alternative reimbursement or value-based contracting models that could be feasible in the short term, given CMS’ decision not to finalize coverage for obesity meds in 2026.